Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Bristol-Myers Squibb (BMS, NYSE: BMY) announced FDA approval for a label extension of Sotyktu (deucravacitinib), its selective TYK2 inhibitor, to include adult patients with active psoriatic arthritis (PsA). The approval, following the drug’s 2022 U.S. launch for plaque psoriasis and 2023 China approval, leverages Sotyktu’s unique allosteric mechanism to address the IL-23/IL-12/IFN-driven inflammation underlying both dermatologic and rheumatologic manifestations of psoriatic disease.

Regulatory Milestone

Mechanism of Action & Differentiation

Pathophysiological Rationale:

• PsA Driver Cytokines: IL-23 and IL-12 promote Th17/Th1 inflammation in joints and entheses
• IFN Signature: Type I interferons contribute to synovitis and bone remodeling
• TYK2 Central Role: Critical signaling node for all three cytokine families; selective inhibition offers efficacy with improved safety

Clinical & Commercial Impact

Competitive Landscape

Portfolio & Strategic Context

• BMS Immunology: Sotyktu anchors BMS’s dermatology-rheumatology franchise alongside Orencia (abatacept) and Zeposia (ozanimod)
• Pipeline Synergy: TYK2 platform being explored for lupus, inflammatory bowel disease, and other interferon-driven diseases
• Revenue Forecast: Analysts project $4-5 billion peak sales for Sotyktu across psoriasis + PsA indications; PsA expansion accelerates trajectory
• China Market: PsA diagnosis rates rising; Sotyktu well-positioned for 2026-2027 label expansion following established psoriasis presence

Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial launch performance, ex-U.S. regulatory expansion, and competitive positioning for Sotyktu in psoriatic arthritis. Actual results may differ due to formulary negotiations, competitive dynamics with JAK inhibitors, and safety data in larger patient populations.-Fineline Info & Tech